Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > DEA cannabis rescheduling model from 3 to 1 is done!
View:
Post by subaru1i on Mar 20, 2024 9:51pm

DEA cannabis rescheduling model from 3 to 1 is done!

I missed it until now because it happened over a long period of time.   The DEA model for rescheduling cannabis from a schedule 1 to schedule 3 is EXTREMELY simple and there is an example of it already.   

The simple part is this:  DOJ/DEA has rescheduled cannabis from a schedule 1 to schedule 3 substance and can be used by FDA registered pharmaceutical companies for pharmaceutical applications.

The example is this:  Medipharm Labs received FDA approval as a pharmaceutical company for cannabinoid active pharmaceutical ingredients.   The DEA approved the import into the U.S. from Medipharm Labs in Canada for pharmaceutical applications.  In our case it was the NIH funding a clinical trial study, for example, the Libby Study at the Keck School of Medicine at University of Southern California.

Medipharms is the example of the model for rescheduling cannabis from 1 to 3 by the DEA because LABS is a pharmaceutical company registed with the FDA and so IS their traditional global pharmaceutical partner.   

Have a nice evening everyone and I do hope no one is caught with their pants and facing a +$10 gap in price when the news hits of LABS and their global pharma partner. 
Comment by subaru1i on Mar 20, 2024 9:53pm
Correction: Got so excited title should read "from 1 to 3 is done!"
Comment by Lvlchange on Mar 20, 2024 10:10pm
Jesus Christ
Comment by QContinuum1 on Mar 21, 2024 7:17am
So you're predicting a schedule change?  How clairvoyant....lol....must be all of that universal background radiation that your missus emanates....
Comment by subaru1 on Mar 21, 2024 10:30am
Desinformation again, he is playing with the emotion of people, poor guy..
Comment by Starkicker on Mar 21, 2024 11:26am
He's desperate  His space dust missus let him buy a $30k Italian trap gun thinking LABS was about to go to $20/share and now he can't afford it.
Comment by subaru1i on Mar 21, 2024 12:37pm
The FDA released a report saying that marijuana does have a legitimate use for medical purposes and recommended the US Drug Enforcement Agency to change its classification from Schedule 1 to Schedule 3. “The definition of a schedule 1 drug says it has no health benefits to it, and, so, obviously, there’s been plenty of research that has documented the multitudes of ways that cannabis can be ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities